Dynamics of serum levels of tumour markers and prognosis of recurrence and survival after liver surgery for colorectal liver metastases

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2861-2864

  Liska, Vaclav ^a   Holubec Jr , L ^a   Treska, V ^a   Skalicky, T ^a   Sutnar, A ^a   Kormunda, S ^a   Pesta, M ^a   Finek, J ^a   Rousarova, M ^a   Topolcan, O ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Colorectal cancer; Liver metastasis; Liver surgery; Prognosis; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; THYMIDINE KINASE; TISSUE POLYPEPTIDE ANTIGEN; TISSUE SPECIFIC POLYPEPTIDE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DISEASE FREE INTERVAL; HUMAN; KAPLAN MEIER METHOD; LIVER METASTASIS; LIVER SURGERY; LOG RANK TEST; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANK SUM TEST; RECURRENT DISEASE; STATISTICAL ANALYSIS; SURVIVAL RATE;

COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 34547806782     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Provenzale D: Screening and surveillance of gastronintestinal cancers. In: Gastrointestinal Cancer. Rustgi AK (ed.). Oxford, Saunders, pp. 193-205, 2003.
2. Hayes DF: Evaluation of tumor markers: an evidence-based guide for determination of clinical utility. In: Oncology: An Evidence-based Approach. Chang AE (ed.). 1st Ed, New York, Springer, pp. 106-112, 2005.
3. Stieber P: Sensible use of tumor markers. J Lab Med 25(9/10): 327-336, 2001.
4. Chang AE and Skibber JM: Evaluation of tumor markers: an evidence-based guide for determination of clinical utility. In: Oncology: An Evidence-based Approach. Chang AE (ed.). 1st ed, New York, Springer, pp. 1753-1767, 2006.
5. Gion M, Mione R, Barioli P and Dittadi R: Dynamic use of tumor markers, rationale-clinical applications and pitfalls. Anticancer Res 16(4B): 2279-2284, 1996.
6. Fong Y, Fortner J, Sun RL, Brennan MF and Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309-318, 1999.
7. Mann CD, Metcalfe MS, Leopardi LN and Maddern GJ: The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg 139: 1168-1172, 2004.
8. Liska V, Treska V, Holubec L, Skalicky T, Sunar A, Topolcan O and Finek J: Prognostic factors of early recurrence of colorectal liver metastases and their usage in clinical praxis. Rozhl Chir 85(4): 163-168, 2006.
9. Nagakura S, Shirai Y, Yokoyama N, Wakai T, Suda T and Hatakeyama K: Major hepatic resection reduces the probability of intrahepatic recurrences following resection of colorectal carcinoma liver metastases. Hepatogastroenterology 50: 779-783, 2003.
10. Liska V, Treska V, Holubec L Jr, Skalicky T, Sutnar A, Topolcan O and Finek J: A partial relaps of a colorectal carcinoma metastatic process following liver surgery-a multifactorical study. Rozhl Chir 85(2): 86-89, 2006.
11. Fleisher M: Practice guidelines and recomendations for use of tumor markers in the clinic. Laboratory Medicine Practice Guidelines 15: 5-56, 2002.
12. 9th European group on tumor markers: Consensus recommendations. Anticancer Res 19: 2785-2820, 1999.
13. Schwartz MK: Tumor markers for colorectal cancer. In: Tumor Markers. Physiology, Pathology, Technology and Clinical Applications. Diamandis EP (ed.)., New York, AACC Press, pp. 253-257, 2002.
14. Bidart JM, Thuillier F and Augereau CH: Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clinical Chemistry 45(10): 1695-1707, 1999.